Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)

被引：25

作者：

Cervantes, Francisco ^{[1
]}

Kiladjian, Jean-Jacques ^{[2
,3
]}

Niederwieser, Dietger ^{[4
]}

Sirulnik, Andres ^{[5
]}

Stalbovskaya, Viktoriya ^{[6
]}

McQuity, Mari ^{[6
]}

Hunter, Deborah S. ^{[7
]}

Levy, Richard S. ^{[7
]}

Passamonti, Francesco ^{[8
,9
]}

Barbui, Tiziano ^{[10
]}

Barosi, Giovanni ^{[11
]}

Gisslinger, Heinz ^{[12
]}

Vannucchi, Alessandro M. ^{[13
]}

Knoops, Laurent ^{[14
]}

Harrison, Claire N. ^{[15
]}

机构：

[1] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[2] Hop St Louis, Paris, France

[3] Univ Paris Diderot, Paris, France

[4] Univ Leipzig, D-04109 Leipzig, Germany

[5] Novartis Pharmaceut, E Hanover, NJ USA

[6] Novartis Pharma AG, Basel, Switzerland

[7] Incyte Corp, Wilmington, DE USA

[8] Osped Circolo Varese, Varese, Italy

[9] Fdn Macchi, Varese, Italy

[10] AO Osped Riuniti Bergamo, Bergamo, Italy

[11] IRCCS Policlin S Matteo Fdn, Pavia, Italy

[12] Med Univ Vienna, Vienna, Austria

[13] Univ Florence, Florence, Italy

[14] Catholic Univ Louvain, Clin Univ St Luc, Duve Inst, B-1200 Brussels, Belgium

[15] Guys & St Thomas NHS FoundationTrust, London, England

来源：

关键词：

D O I：

10.1182/blood.V120.21.801.801

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

801

引用

页数：2